Smiths Detection equips Leonardo di Vinci International Airport in Rome with advanced carry-on baggage screening technology
14.9.2022 16:03:00 EEST | Business Wire | Press release
Smiths Detection, a global leader in threat detection and security inspection technologies, announces that it has begun installing 30 HI-SCAN 6040 CTiX carry-on baggage screening systems at Leonardo di Vinci International Airport in Rome. The installation of this world-leading technology reflects the airport’s high standards for passenger service excellence and process automation, having recently been awarded the ACI Best Airport in Europe for the fourth time in the last five years.
Smiths Detection’s HI-SCAN 6040 CTiX is a computed tomography (CT) X-ray scanner producing high-resolution volumetric 3D images for quicker and deeper baggage assessment and low false-alarm rates. The scanners allow for electronics and liquids to remain in bags, speeding up passenger screening and reducing touchpoints.
The combination of the CT X-ray scanners, alongside 45 already supplied Smiths Detection IONSCAN 600 trace detectors, will further improve security and operational efficiency. The IONSCAN 600 is a highly sensitive, non-radioactive, lightweight, portable desktop system that detects and identifies trace amounts of explosives and narcotics.
The HI-SCAN 6040 CTiX can be equipped with Smiths Detection’s object recognition software, iCMORE, which uses advanced algorithms to reduce the burden on operators – and potential errors – by automating the detection process for prohibited items.
Stefano Scardigli, Senior Key Account, Smiths Detection said: “We are delighted to supply Leonardo di Vinci Rome International Airport with 30 HI-SCAN 6040 CTiX scanners. Utilising 3D imagery, our scanners offer the advanced screening of carry-on baggage, enhancing security and improving operational efficiency. Being able to leave electronics and liquids in carry-on baggage will help expedite the screening process, especially in light of the well documented staffing pressures at airports around the world.”
Marco Stramaccioni, Chief Executive Officer of ADR Security for Leonardo da Vinci Rome International Airport said: “Aeroporti di Roma looks forward to be a frontrunner for passenger experience and security at Leonardo di Vinci Rome International Airport. As passenger numbers increase, we will be well placed to efficiently screen passengers, reducing the burden on our operators. By harnessing the power of CT technology, we have futureproofed our security checkpoints.”
Smiths Detection’s HI-SCAN 6040 CTiX is certified by the U.S. Transportation Security Administration (TSA) under the Accessible Property Screening System (APSS) program to detection standard 6.2, Level 1, permitting the scanner to operate at an enhanced level with lower false alarm rates, as well as ECAC and STAC EDS CB C3 approval.
###
About the Products
- HI-SCAN 6040 CTiX: https://www.smithsdetection.com/products/hi-scan-6040-ctix/
- IONSCAN 600: https://www.smithsdetection.com/products/ionscan-600/
- iCMORE: https://www.smithsdetection.com/products/icmore/
About Smiths Detection
Smiths Detection, a division of Smiths Group, is a global leader in inspection and detection technologies for the air transport, ports and borders, armed forces and urban security markets. With more than 70 years of experience in the field, we offer the necessary solutions to protect society from the threats posed by explosives, prohibited weapons, contraband, toxic chemical agents and narcotics.
Our mission is simple: to ensure the security, peace of mind and freedom of movement on which the world depends.
Please visit http://www.smithsdetection.com/ for further information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005455/en/
Contact information
FTI Consulting:
Tom Hufton/Georgina Reeves/Zoe Williams
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000
Smiths Detection:
Sophie Mills, Head of Corporate Communications
sophie.mills@smithsdetection.com
+44 (0)73 8423 6474
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom